Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.

被引：5
|
作者：
Wainberg, Zev A.
Shapiro, Geoffrey
Curigliano, Giuseppe
Leong, Stephen
Kristeleit, Rebecca Sophie
Maqueda, Maria Alsina
Britten, Carolyn D.
Milella, Michele
Middleton, Mark R.
Olszanski, Anthony J.
Vaishampayan, Ulka N.
Lopez-Martin, Jose A.
Gelmon, Karen A.
Brega, Nicoletta
Pierce, Kristen J.
Perea, Rachelle
Houk, Brett Edward
Pathan, Nuzhat
Gollerkeri, Ashwin
Razak, Albiruni R. A.
机构：
[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Ist Europeo Oncol, Milan, Italy
[4] Univ Colorado, Ctr Canc, Aurora, CO USA
[5] UCL, Inst Canc, London, England
[6] Hosp Valle De Hebron, Barcelona, Spain
[7] Med Univ S Carolina, Charleston, SC 29425 USA
[8] Regina Elena Inst Canc Res, Med Oncol A, Rome, Italy
[9] Oxford NIHR Biomed Res Ctr, Oxford, England
[10] Temple Hlth, Fox Chase Canc Ctr, Philadelphia, PA USA
[11] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[12] Hosp 12 Octubre, E-28041 Madrid, Spain
[13] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[14] Pfizer Italia, Milan, Italy
[15] Pfizer Oncol, Groton, CT USA
[16] Pfizer Worldwide Res & Dev, San Diego, CA USA
[17] Pfizer Inc, Carlsbad, CA USA
[18] Pfizer, San Diego, CA USA
[19] Pfizer BioTherapeut, Cambridge, MA USA
[20] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2590
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
    Yuan, Jing
    Mehta, Pramod P.
    Yin, Min-Jean
    Sun, Shaoxian
    Zou, Aihua
    Chen, Jeffrey
    Rafidi, Kristina
    Feng, Zheng
    Nickel, Jeffrey
    Engebretsen, Jon
    Hallin, Jill
    Blasina, Alessandra
    Zhang, Eric
    Nguyen, Leslie
    Sun, Minghao
    Vogt, Peter K.
    McHarg, Aileen
    Cheng, Hengmiao
    Christensen, James G.
    Kan, Julie L. C.
    Bagrodia, Shubha
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2189 - 2199
  • [22] Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
    Chen, Ming-Huang
    Chiang, Kun-Chun
    Cheng, Chi-Tung
    Huang, Shih-Chiang
    Chen, Yeng-Yang
    Chen, Tsung-Wen
    Yeh, Ta-Sen
    Jan, Yi-Yin
    Wang, Hsi-Ming
    Weng, Jiang-Jie
    Chang, Peter Mu-Hsin
    Liu, Chun-Yu
    Li, Chung-Pin
    Chao, Yee
    Chen, Ming-Han
    Huang, Chi-Ying F.
    Yeh, Chun-Nan
    ONCOTARGET, 2014, 5 (09) : 2372 - 2389
  • [23] Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates
    Mazzoletti, Marco
    Bortolin, Francesca
    Brunelli, Laura
    Pastorelli, Roberta
    Di Giandomenico, Silvana
    Erba, Eugenio
    Ubezio, Paolo
    Broggini, Massimo
    CANCER RESEARCH, 2011, 71 (13) : 4573 - 4584
  • [24] Discovery of the potent PI3K/mTOR dual inhibitor PF-04979064
    Cheng, Hengmiao
    Bagrodia, Shubha
    Bailey, Simon
    Baxi, Sangita M.
    Goulet, Lance
    Guo, Lisa
    Hoffman, Jacqui
    Johnson, Ted O.
    Johnson, Ted W.
    Li, Chunze
    Li, John
    Liu, Kevin
    Liu, Zhengyu
    Marx, Matthew A.
    Paderes, Gigi
    Sun, Shaoxian
    Walls, Marlena
    Wells, Peter A.
    Yang, Anle
    Yin, Min-Jean
    Zhu, Jingjiang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [25] Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
    Britten, Carolyn D.
    Adjei, Alex A.
    Millham, Robert
    Houk, Brett E.
    Borzillo, Gary
    Pierce, Kristen
    Wainberg, Zev A.
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 510 - 517
  • [26] Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
    Carolyn D. Britten
    Alex A. Adjei
    Robert Millham
    Brett E. Houk
    Gary Borzillo
    Kristen Pierce
    Zev A. Wainberg
    Patricia M. LoRusso
    Investigational New Drugs, 2014, 32 : 510 - 517
  • [27] Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
    Carolyn D. Britten
    Alex A. Adjei
    Robert Millham
    Brett E. Houk
    Gary Borzillo
    Kristen Pierce
    Zev A. Wainberg
    Patricia M. LoRusso
    Investigational New Drugs, 2014, 32 (3) : 575 - 575
  • [28] Synthesis of PF-04691502, a highly potent PI3K/mTOR dual inhibitor
    Hoffman, Jacqui
    Bailey, Simon
    Cheng, Hengmiao
    Kania, Robert
    Jai, Lei
    Nambu, Mitch
    Ninkovich, Sacha
    Pairish, Mason
    Srirangam, Jay
    Wang, Xiaolong
    Le, Phuong
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [29] COMBINATION OF HDAC INHIBITOR AND PI3K/MTOR INHIBITOR SYNERGISTICALLY INDUCES APOPTOSIS IN DIPG
    Barnett, Katie
    Kwon, HyukJean
    Raabe, Eric
    Eberhart, Charles
    NEURO-ONCOLOGY, 2022, 24 : 212 - 213
  • [30] The PI3K/mTOR dual inhibitor PF-04691502 shows antitumor activity in Sezary cells and in a xenograft mouse model
    Bresin, Antonella
    Cristofoletti, Cristina
    Monzo, Francesca
    Caprini, Elisabetta
    Citterich, Mauro Helmer
    Frezzolini, Alessandra
    Monopoli, Alessandro
    Benucci, Roberto
    Cantonetti, Maria
    Scala, Enrico
    Russo, Giandomenico
    Narducci, Maria Grazia
    CANCER RESEARCH, 2019, 79 (13)
12345